Uploaded December 2025 | Updated September 2026, 2 weeks ago
Welcome to another compelling episode of #ExpertTalk by EverythingALS!
In this session, we’re joined by Dr. Suma Babu, Co-Director, Neurological Research Institute, Massachusetts General Brigham and Associate Professor of Neurology, Harvard Medical School
Dr Babu discussed:
• Big picture: This talk introduced Healey ALS MyMatch, a new approach to running faster, smarter early-phase ALS clinical trials by focusing on biology, biomarkers, and patient-centered design.
• Why it matters: MyMatch aims to reduce trial delays, improve access, and increase the chances of identifying promising treatments by better matching people living with ALS to the right studies.
• What’s happening now: The program has already launched its first trial and is building a growing pipeline of additional therapies, with more studies expected in the near future.
• What participants should know: MyMatch is designed for people with ALS who meet specific eligibility criteria, while expanded access programs and other pathways remain important options for those who do not qualify.
📲 Download the EverythingALS App:
- Google Playstore: bit.ly/4nXqIYy
- App Store: bit.ly/42tPBmh
Follow EverythingALS:
► Website: everythingals.org
► Twitter: https://x.com/everything_als
► LinkedIn: linkedin.com/everythingals
► Facebook: facebook.com/EverythingALS
► Subscribe for more Expert Talks: youtube.com/c/everythingals
#ExpertTalk #ALSResearch #EverythingALS #ALSCommunity #NeurodegenerativeDiseases #PatientCenteredResearch #ALSAdvocacy #CollaborativeScience #ALSNetwork #MotorNeuronDisease #ALSUpdates #ALSExperts #HealeyMyMatch
🔔 If you're passionate about advancing ALS care and research — like, subscribe, and turn on notifications.
Share this episode to raise awareness and support for the ALS community.
Welcome to another compelling episode of #ExpertTalk by EverythingALS!
In this session, we’re joined by Dr. Suma Babu, Co-Director, Neurological Research Institute, Massachusetts General Brigham and Associate Professor of Neurology, Harvard Medical School
Dr Babu discussed:
• Big picture: This talk introduced Healey ALS MyMatch, a new approach to running faster, smarter early-phase ALS clinical trials by focusing on biology, biomarkers, and patient-centered design.
• Why it matters: MyMatch aims to reduce trial delays, improve access, and increase the chances of identifying promising treatments by better matching people living with ALS to the right studies.
• What’s happening now: The program has already launched its first trial and is building a growing pipeline of additional therapies, with more studies expected in the near future.
• What participants should know: MyMatch is designed for people with ALS who meet specific eligibility criteria, while expanded access programs and other pathways remain important options for those who do not qualify.
📲 Download the EverythingALS App:
- Google Playstore: bit.ly/4nXqIYy
- App Store: bit.ly/42tPBmh
Follow EverythingALS:
► Website: everythingals.org
► Twitter: https://x.com/everything_als
► LinkedIn: linkedin.com/everythingals
► Facebook: facebook.com/EverythingALS
► Subscribe for more Expert Talks: youtube.com/c/everythingals
#ExpertTalk #ALSResearch #EverythingALS #ALSCommunity #NeurodegenerativeDiseases #PatientCenteredResearch #ALSAdvocacy #CollaborativeScience #ALSNetwork #MotorNeuronDisease #ALSUpdates #ALSExperts #HealeyMyMatch
🔔 If you're passionate about advancing ALS care and research — like, subscribe, and turn on notifications.
Share this episode to raise awareness and support for the ALS community.
